Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination CD19/CD22 CAR-T for Refractory B-lineage Malignancies
NCT02903810Phase 2Unknown
- Sponsor
- Xuzhou Medical University
- Start
- Sep 2016
- Primary completion
- Dec 2018
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CD22-BBz CAR T cells in B-cell leukemia (BCL) and B cell lymphoma, sponsored by Xuzhou Medical University. Primary endpoint: Incidence of adverse events defined as dose-limited toxicity at 30 days. Status: unknown.
02
Drugs
CD22-BBz CAR T cells
03
Conditions
B-cell leukemia (BCL)B cell lymphoma
Beyond the preview
Go deeper on NCT02903810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02903810.